Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy
- 26 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 37 (3), 1-14
- https://doi.org/10.1007/s11095-020-2781-6
Abstract
Purpose A patient was denoted to be generic brittle (GB) if they had a negative opinion about generics (e.g. prior history of a switch problem) or took the innovator brand of their most problematic anti-epileptic drug (AED) when generic was available. The aim of this hypothesis-generating study was to assess possible genetic and physiologic differences between GB and not GB patients with epilepsy. Methods Patients (n = 148) with epilepsy were previously characterized as being either GB or not GB. Blood was collected from each subject for genotyping and physiologic testing. Genotyping for 24 single nucleotide polymorphisms (SNPs) and two copy number variants (CNVs) was performed across 12 genes in each patient. Forty-four physiologic tests were conducted in each patient. Chi square analysis was performed to assess for associations between genotyping results and GB status, as well as between physiologic test results and GB status. Results No SNP or CNV discriminated GB status in genetic analysis (genotype or allele frequency). Physiologic test results in this study were not associated with GB status. Conclusions Questions from neurologists and patients about generics is frequently based on applicability of generic drug standards to individual subjects. However, findings here in patients with epilepsy did not uncover genetic or physiologic reasons that explained which patients were GB and which were not GB.Keywords
Funding Information
- U.S. Food and Drug Administration (HHSF223201400188C)
This publication has 66 references indexed in Scilit:
- Therapeutic potential for phenytoin: targeting Nav1.5 sodium channels to reduce migration and invasion in metastatic breast cancerBreast Cancer Research and Treatment, 2012
- PharmGKB summaryPharmacogenetics and Genomics, 2011
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Patients’ attitudes towards generic drug substitution in JapanHealth Policy, 2011
- Molecular Model of Anticonvulsant Drug Binding to the Voltage-Gated Sodium Channel Inner PoreMolecular Pharmacology, 2010
- The clinical impact of pharmacogenetics on the treatment of epilepsyEpilepsia, 2009
- Multiplex PCR Detection of GSTM1, GSTT1, and GSTP1 Gene Variants: Simultaneously Detecting GSTM1 and GSTT1 Gene Copy Number and the Allelic Status of the GSTP1 Ile105Val Genetic VariantThe Journal of Molecular Diagnostics, 2007
- DrugBank: a knowledgebase for drugs, drug actions and drug targetsNucleic Acids Research, 2007
- Update to The PhRMA Perspective on Population and Individual BioequivalenceThe Journal of Clinical Pharmacology, 2000
- Type I and Type II Error in Multiple ComparisonsThe Journal of Psychology, 1996